[Consensus of Chinese Experts on Medical Treatment of Advanced Lung Cancer 
in the Elderly (2022 Edition)].

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Cutting-edge advances in endocrine therapy for breast cancer (Review).Oncology letters · 2026
   Review
2. Predictive role of vulnerable elderly study-13 screening tools in chemotherapy-related toxicity in elderly patients with lung cancer.Scientific reports · 2026
   Observational
3. Prognostic nomogram for cancer-specific survival in adenosquamous carcinoma of lung patients treated with chemotherapy: A SEER-based retrospective cohort study.Medicine · 2026
   Article
4. Artificial intelligence-assisted machine learning models for predicting lung cancer survival.Asia-Pacific journal of oncology nursing · 2025
   Article
5. Validation of the Longitudinal Effect of an Integrated Nursing Intervention Based on the Integrated Theory of Health Behavior Change (ITHBC) on Multidimensional Health Indicators in Older Radiotherapy Patients.Clinical interventions in aging · 2025
   Article
6. [Relationship between GTSE1 and Cell Cycle and Potential Regulatory Mechanisms 
in Lung Cancer Cells].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
   Review
7. [Current Status and Prospect of PD-1/PD-L1 Immune Checkpoint Inhibitor Therapy 
in Elderly Patients with Advanced NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024
   Review
8. Efficacy and Safety Analysis of Immune Checkpoint Inhibitors plus Angiogenesis Inhibitors for the Treatment of Advanced Driver-negative NSCLC in Elderly Patients: A Retrospective Study.Journal of Cancer · 2023
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as